메뉴 건너뛰기




Volumn 12, Issue 6, 2010, Pages 548-551

Safety of pramlintide added to mealtime insulin in patients with type 1 or type 2 diabetes: A large observational study

Author keywords

Observational study; Patient ascertained severe hypoglycaemia; Pramlintide; Safety; Type 1 diabetes; Type 2 diabetes

Indexed keywords

HEMOGLOBIN A1C; INSULIN; PRAMLINTIDE;

EID: 77953199798     PISSN: 14628902     EISSN: 14631326     Source Type: Journal    
DOI: 10.1111/j.1463-1326.2010.01201.x     Document Type: Article
Times cited : (17)

References (11)
  • 1
    • 77953228575 scopus 로고    scopus 로고
    • Amylin Pharmaceuticals Inc., San Diego, CA: Amylin Pharmaceuticals, Inc.,
    • 2008, Amylin Pharmaceuticals Inc., San Diego, CA: Amylin Pharmaceuticals, Inc.,
    • (2008)
  • 2
    • 0036548068 scopus 로고    scopus 로고
    • A randomized study and open-label extension evaluating the long-term efficacy of pramlintide as an adjunct to insulin therapy in type 1 diabetes
    • Whitehouse F, Kruger DF, Fineman M. A randomized study and open-label extension evaluating the long-term efficacy of pramlintide as an adjunct to insulin therapy in type 1 diabetes. Diabetes Care 2002, 25:724-730.
    • (2002) Diabetes Care , vol.25 , pp. 724-730
    • Whitehouse, F.1    Kruger, D.F.2    Fineman, M.3
  • 3
    • 0036238808 scopus 로고    scopus 로고
    • Adjunctive therapy with the amylin analogue pramlintide leads to a combined improvement in glycemic and weight control in insulin-treated subjects with type 2 diabetes
    • Ratner RE, Want LL, Fineman MS. Adjunctive therapy with the amylin analogue pramlintide leads to a combined improvement in glycemic and weight control in insulin-treated subjects with type 2 diabetes. Diabetes Technol Ther 2002, 4:51-61.
    • (2002) Diabetes Technol Ther , vol.4 , pp. 51-61
    • Ratner, R.E.1    Want, L.L.2    Fineman, M.S.3
  • 4
    • 33747789575 scopus 로고    scopus 로고
    • Pramlintide in the management of insulin-using patients with type 2 and type 1 diabetes
    • Pullman J, Darsow T, Frias JP. Pramlintide in the management of insulin-using patients with type 2 and type 1 diabetes. Vasc Health Risk Manage 2006, 2:203-212.
    • (2006) Vasc Health Risk Manage , vol.2 , pp. 203-212
    • Pullman, J.1    Darsow, T.2    Frias, J.P.3
  • 5
    • 33747763918 scopus 로고    scopus 로고
    • A double-blind, placebo-controlled trial assessing pramlintide treatment in the setting of intensive insulin therapy in type 1 diabetes
    • Edelman S, Garg S, Frias J. A double-blind, placebo-controlled trial assessing pramlintide treatment in the setting of intensive insulin therapy in type 1 diabetes. Diabetes Care 2006, 29:2189-2195.
    • (2006) Diabetes Care , vol.29 , pp. 2189-2195
    • Edelman, S.1    Garg, S.2    Frias, J.3
  • 6
    • 34247535904 scopus 로고    scopus 로고
    • Pramlintide as an adjunct to insulin in patients with type 2 diabetes in a clinical practice setting reduced A1C, postprandial glucose excursions and weight
    • Karl D, Philis-Tsimikas A, Darsow T. Pramlintide as an adjunct to insulin in patients with type 2 diabetes in a clinical practice setting reduced A1C, postprandial glucose excursions and weight. Diabetes Technol Ther 2007, 9:191-199.
    • (2007) Diabetes Technol Ther , vol.9 , pp. 191-199
    • Karl, D.1    Philis-Tsimikas, A.2    Darsow, T.3
  • 7
    • 0041666594 scopus 로고    scopus 로고
    • Frequency of severe hypoglycemia requiring emergency treatment in type 1 and type 2 diabetes: a population-based study of health service resource use
    • Leese GP, Wang J, Broomhall J. Frequency of severe hypoglycemia requiring emergency treatment in type 1 and type 2 diabetes: a population-based study of health service resource use. Diabetes Care 2003, 26:1176-1180.
    • (2003) Diabetes Care , vol.26 , pp. 1176-1180
    • Leese, G.P.1    Wang, J.2    Broomhall, J.3
  • 8
    • 0023278491 scopus 로고
    • Effects of age, duration and treatment of insulin-dependent diabetes mellitus on residual beta-cell function: observations during eligibility testing for the Diabetes Control and Complications Trial (DCCT)
    • DCCT Research Group
    • Effects of age, duration and treatment of insulin-dependent diabetes mellitus on residual beta-cell function: observations during eligibility testing for the Diabetes Control and Complications Trial (DCCT). J Clin Endocrinol Metab 1987, 65:30-36. DCCT Research Group
    • (1987) J Clin Endocrinol Metab , vol.65 , pp. 30-36
  • 10
    • 0028292096 scopus 로고
    • Frequency of severe hypoglycemia in patients with type I diabetes with impaired awareness of hypoglycemia
    • Gold AE, MacLeod KM, Frier BM. Frequency of severe hypoglycemia in patients with type I diabetes with impaired awareness of hypoglycemia. Diabetes Care 1994, 17:697-703.
    • (1994) Diabetes Care , vol.17 , pp. 697-703
    • Gold, A.E.1    MacLeod, K.M.2    Frier, B.M.3
  • 11
    • 0027409534 scopus 로고
    • Frequency and morbidity of severe hypoglycaemia in insulin-treated diabetic patients
    • MacLeod KM, Hepburn DA, Frier BM. Frequency and morbidity of severe hypoglycaemia in insulin-treated diabetic patients. Diabet Med 1993, 10:238-245.
    • (1993) Diabet Med , vol.10 , pp. 238-245
    • MacLeod, K.M.1    Hepburn, D.A.2    Frier, B.M.3


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.